The MoBot Report

October 24, 2024

DENVER, Colo., Oct 24, 2024 (247marketnews.com)- MoBot’s recent alerts involved Monopar (NASDAQ: MNPR), AstraZeneca (NASDAQ: AZN), Bright Minds (NASDAQ: DRUG), ZenaTech (NASDAQ:ZENA), and Nexalin (NASDAQ: NXL).

Mobot alerted Monopar Therapeutics (NASDAQ: MNPR) Sep 25 at $5.213 and several times since, including this morning at $7.139.

Monopar hit a high of $36.35 after announcing that it entered into an exclusive worldwide license agreement with Alexion, AstraZeneca Rare Disease (NASDAQ: AZN) for ALXN-1840 (bis-choline tetrathiomolybdate), a drug candidate for Wilson disease that met its primary endpoint  in a Phase 3 clinical trial.

Chandler D. Robinson, MD, Monopar’s Co-Founder and CEO, previously researched tetrathiomolybdate at the laboratory bench, published his results in Science, and helped launch a company around what became known as ALXN-1840, commented, “Alexion has generated a substantial clinical data package on ALXN-1840, including a completed Pivotal Phase 3 clinical trial. The medical data gathered from Alexion’s clinical trials furthers our understanding of Wilson disease and stands to benefit this community.”

Monopar will try to hold their games as well as Bright Minds (NASDAQ: DRUG), which MoBot alerted at $1.426, on Oct 14, before it ran to a new 52-week high of $79.02. Bright Minds continues to trade around the $50 level.

Bright Minds (NASDAQ: DRUG) stated, on Monday, that it is again collaborating with Firefly Neuroscience (NASDAQ: AIFF) to thoroughly evaluate the electroencephalogram (EEG) data in Bright Minds’ BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE).

ZenaTech (NASDAQ:ZENA) was a premarket play that Mobot alerted at $2.29 and reached $3.26 in the premarket, after stating that its ZenaDrone subsidiary is acquiring a design patent, number US D1,005,883 S, for a drone design pertaining to its ZenaDrone 1000 second-generation drone design, which is an autonomous quadcopter with eight rotors.

CEO Shaun Passley, Ph.D, stated, “The expansion of our patent portfolio is integral to building company assets as well as protecting our unique drone hardware inventions. This patent is key to flight time and performance improvements of the ZenaDrone 1000, facilitating continued development for Agriculture, Defense, Oil and Gas, Utilities, as well as specific applications like crop management, military cargo, and others where we see growing demand.”

Nexalin (NASDAQ: NXL) caught MoBot’s attention last week at $1.03 and multiple times since, including today’s first alert at $1.756 and less than 30 minutes later, it eclipsed $$2.45.

Yesterday, Nexalin stated that it plans to commence a new clinical trial in collaboration with the University of California, San Diego (UCSD) and that Dr Ming Xiong Huang, the UCSD principal investigator, will utilize his affiliation with the San Diego VA to recruit some of the patients for the study who have been victims of Traumatic Brain Injury (TBI). This trial will focus on the effectiveness of Nexalin’s Gen-3 Halo headset, designed to be used in a virtual clinic model, allowing patients to receive treatment from the convenience and privacy of their own home thus overriding the inconvenience and stigma of visiting a psychiatry office or VA Hospital.

Please go to 247marketnews.com to sign up for free MoBot alerts and view Mobot’s real time data.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (MNPR, AZN, DRUG, ZENA, NXL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.